Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Download PDF Copy

Apr 29 2010

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

In this complete response letter there are no requests for new pre-clinical or clinical trials. The sole issue raised in this letter concerns a deficiency of the manufacturing facility for this application. The manufacturer has responded to the FDA and continues to work with the FDA to resolve the matter. The facility only manufactures COLAZAL^® Capsules and GIAZO™ Tablets for Salix.

Source:

Salix Pharmaceuticals, Ltd.,

Posted in: Medical Condition News | Pharmaceutical News

Tags: Ascorbic Acid, Azathioprine, Food, Gastroenterology, Hydrocortisone, Manufacturing, Metoclopramide, New Drug Application, Pharmaceuticals, Potassium, Preclinical, Ulcerative Colitis

Comments (0)

Download PDF Copy

Suggested Reading

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Aging reduces cancer risk by limiting cell regeneration

Aging reduces cancer risk by limiting cell regeneration

Danish studies find increased risk of optic nerve damage with diabetes medicine

Danish studies find increased risk of optic nerve damage with diabetes medicine

Breakthrough in HWE reaction offers pathway for anti-cancer drug development

Breakthrough in HWE reaction offers pathway for anti-cancer drug development

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

New study reveals complex attitudes toward psychedelic therapy

New study reveals complex attitudes toward psychedelic therapy

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

New modular strategy reduces piperidine synthesis steps for pharmaceuticals

New modular strategy reduces piperidine synthesis steps for pharmaceuticals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Annona squamosa extracts show promise in treating pain and arthritis